Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: Results from the SWEFOT trial

RMD Open

Volumn 3, Issue 2, 2017, Pages

  Levitsky, Adrian ^a   Brismar, Kerstin ^a   Hafström, Ingiäld ^a   Hambardzumyan, Karen ^a   Lourdudoss, Cecilia ^a   Van Vollenhoven, Ronald F ^a,b   Saevarsdottir, Saedis ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

anti TNF; body mass index; disease activity; DMARDs (synthetic); early rheumatoid arthritis; predictions and projections; treatment

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADULT; AGE; ARTHRALGIA; ARTICLE; BODY MASS; CLINICAL OUTCOME; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; EARLY RHEUMATOID ARTHRITIS; EROSION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBESITY; OPEN STUDY; PAIN; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEX; SHARP VAN DER HEIJDE SCORE; SMOKING; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

EID: 85027308938     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2017-000458     Document Type: Article

References (27)

1. Neovius M, Simard JF, Klareskog L, et al. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. Ann Rheum Dis 2011; 70: 1407-14
2. Neovius M, Simard JF, Askling J, et al. How large are the productivity losses in contemporary patients with RA. and how soon in relation to diagnosis do they develop? Ann Rheum Dis 2011; 70: 1010-5
3. Eriksson JK, Neovius M, Bratt J, et al. Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial. JAMA Intern Med 2013; 173: 1407-14
4. Cutolo M, Kitas GD, van Riel PL. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Semin Arthritis Rheum 2014; 43: 479-88
5. Vidal C, Barnetche T, Morel J, et al. Association of Body Mass Index Categories with Disease Activity and Radiographic Joint damage in Rheumatoid Arthritis: a Systematic Review and Metaanalysis. J Rheumatol 2015; 42: 2261-9
6. Liu Y, Hazlewood GS, Kaplan GG, et al. Impact of obesity on remission and disease activity in Rheumatoid Arthritis: a Systematic Review and Meta-Analysis. Arthritis Care Res 2017; 69
7. Sandberg ME, Bengtsson C, Kallberg H, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis 2014; 73: 2029-33
8. Ajeganova S, Andersson ML, Hafstrom I, et al. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res 2013; 65: 78-87
9. Baker JF, Ostergaard M, George M, et al. Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years. Ann Rheum Dis 2014; 73: 1923-8
10. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009; 374: 459-66
11. van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexaterefractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group swefot trial. Lancet 2012; 379: 1712-20
12. Saevarsdottir S, Wallin H, Seddighzadeh M, et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 2011; 70: 469-75
13. Saevarsdottir S, Rezaei H, Geborek P, et al. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis 2015; 74: 1509-14
14. Gremese E, Carletto A, Padovan M, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor-in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res 2013; 65: 94-100
15. Klaasen R, Wijbrandts CA, Gerlag DM, et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2011; 63: 359-64
16. Daien CI, Sellam J. Obesity and inflammatory arthritis: impact on occurrence, disease characteristics and therapeutic response. RMD Open 2015; 1: e000012
17. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90
18. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2008; 58(2 Suppl): S126-35
19. Heimans L, van den Broek M, le Cessie S, et al. Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res 2013; 65: 1235-42
20. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008; 37: 635-46
21. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-83
22. Del Prete A, Salvi V, Sozzani S. Adipokines as potential biomarkers in rheumatoid arthritis. Mediators Inflamm 2014; 2014: 1-11
23. Lee SW, Park MC, Park YB, et al. Measurement of the serum leptin level could assist disease activity monitoring in rheumatoid arthritis. Rheumatol Int 2007; 27: 537-40
24. Wang QP, Li XP, Wang M, et al. Adiponectin exerts its negative effect on bone metabolism via OPG/RANKL pathway: an in vivo study. Endocrine 2014; 47: 845-53
25. Meyer M, Sellam J, Fellahi S, et al. Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther 2013; 15: R210
26. Giles JT, Bridges SL Jr, O'Dell JR, et al. Increasing Circulating Adiponectin after DMARD Initiation Is Associated with Radiographic Progression in Early Aggressive RA, Regardless of Treatment Strategy. Arthritis Rheumatol 2015; 67(suppl 10
27. Takahashi C, Kaneko Y, Okano Y, et al. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open 2017; 3: e000363